Upcoming Forms Revisions

Audience: International and Domestic Data Managers and Medical Directors

Upcoming Forms Revisions

CIBMTR plans to revise numerous data collection forms over the next few months. As part of this important process, we are seeking Data Managers who are interested in providing their input on the form revision process. The goal is to ensure each form captures current and relevant data, particularly as new definitions or tests have been accepted for use in the field. This collaborative process also ensures the burden of data collection is reviewed and acceptable.

Please contact Stephanie Meyers at smeyers@mcw.edu if you are interested in participating by Tuesday, June 22nd.

Transplant Essential Data Forms

The Forms to be revised include:
- 2400 – Pre-Transplant Essential Data
- 2402 – Pre-Transplant Essential Data: Disease Classification
- 2004 – Infectious Disease Markers
- 2005 – Confirmation of HLA Typing
- 2006 – Hematopoietic Stem Cell Transplant (HCT) Infusion
- 2450 – Post-Transplant Essential Data

Although there will not be a formal committee for these revisions, it is strongly encouraged to submit suggestions for forms changes. To do this, please review the forms and send any suggested improvements / changes via CIBMTR Center Support Form Revision by Tuesday, June 22nd.

Immune Deficiencies and Cellular Therapy Forms

The forms to be revised include:
- 2031 – Immune Deficiencies Pre-Transplant
- 2131 – Immune Deficiencies Post-Transplant
- 4000 – Pre-Cellular Therapy Essential Data
- 4003 – Cellular Therapy Product
- 4006 – Cellular Therapy Infusion
- 4100 – Cellular Therapy Essential Data Follow-Up

There are two ways in which you can contribute:

1) **Submit suggestions for forms changes.** Review the forms and send any suggested improvements / changes via CIBMTR Center Support > Form Revision by Tuesday, June 22nd. This may include clarification to questions, potentially new data to collect, or reformatting the way data are captured. All suggestions are important!

2) **Volunteer for a Form Revision Committee.** Data Manager representation is very valuable to the overall committee goal of determining content changes.
   a. For Immune Deficiencies, participating via a conference call will require at least a two-hour commitment. The process of identifying non-relevant data has occurred and will be reviewed as part of the meeting. All suggestions received by key stakeholders will also be reviewed and discussed.
   b. For Cellular Therapy, we expect the discussions will require approximately three, two-hour meetings but will adjust as needed.

Meetings are anticipated to occur throughout July and August. Dates/times will be provided at a later date. Please contact Stephanie Meyers at smeyers@mcw.edu if you are interested in participating by Tuesday, June 22nd.